Yan Q Chen, Ye Yang, Eugene Y Zhen, Thomas P Beyer, Hongxia Li, Yi Wen, Mariam Ehsani, Nicholas Jackson, Katherine Xie, Hyesoo Jung, Julia L Scheithauer, Anni Kumari, Gabriel Birrane, Anna M Russell, Deepa Balasubramaniam, Zhongping Liao, Robert W Siegel, Yuewei Qian, Michael Ploug, Stephen G Young, Robert J Konrad
Apolipoprotein AV (APOA5) lowers plasma triglyceride (TG) levels by binding to the angiopoietin-like protein 3/8 complex (ANGPTL3/8) and suppressing its capacity to inhibit lipoprotein lipase (LPL) catalytic activity and its ability to detach LPL from binding sites within capillaries. However, the sequences in APOA5 that are required for suppressing ANGPTL3/8 activity have never been defined. A clue to the identity of those sequences was the presence of severe hypertriglyceridemia in two patients harboring an APOA5 mutation that truncates APOA5 by 35 residues ("APOA5Δ35")...
April 23, 2024: Proceedings of the National Academy of Sciences of the United States of America